Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026) [Globe and Mail, The (Toronto, Canada)]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Globe and Mail, The
Agios has a potential pipeline catalyst in 2026 with tebapivat. Shares in Agios Pharmaceuticals (NASDAQ: AGIO) crashed by 26.8% in the week as of the time of writing. The move comes after a much larger pharmaceutical company, Novo Nordisk (NYSE: NVO) , announced top-line results from a class of drug to treat sickle cell disease (SCD) that implied superiority over Agios' rival drug mitapavit. Novo Nordisk's latest announcement Both drugs, Novo's etavopivat and Agios' mitapivat, are in the same class of oral pyruvate kinase (PK) activators that affect red blood cell metabolism in patients with sickle cell disease. However, Novo describes etavopivat as a pyruvate kinase-R (PKR) activator, reflecting that it specifically targets PKR (Protein Kinase R). Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Novo's to
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- BofA Reaffirms Buy Rating for Agios Pharmaceuticals (AGIO) [Yahoo! Finance]Yahoo! Finance
- Do Upbeat EPS Revisions Before Earnings Quietly Reframe Agios Pharmaceuticals' (AGIO) Risk-Reward Profile? [Yahoo! Finance]Yahoo! Finance
- Agios (AGIO) Q2 2025 Earnings Call Transcript [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Agios (AGIO) Q3 2025 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Agios Pharmaceuticals (AGIO) had its price target lowered by Bank of America Corporation from $44.00 to $41.00. They now have a "buy" rating on the stock.MarketBeat
AGIO
Earnings
- 2/12/26 - Miss
AGIO
Sec Filings
- 4/24/26 - Form ARS
- 4/24/26 - Form DEFA14A
- 4/24/26 - Form DEF
- AGIO's page on the SEC website